SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Pluri Agrees to License U.S. Regenerative Medicine Portfolio to ZEO

Pluri agreed to grant ZEO ScientifiX an exclusive U.S. license to manufacture and commercialize its regenerative medicine portfolio. The partnership could expand into Latin America; Pluri is expected to own 50% of ZEO following contemplated share issuances.

PLUR

Related stories